1. Gonorrhea Sexually Transmitted Disease Surveillance 2010
Division of STD Prevention

2. Gonorrhea—Rates, United States, 1941–2010
Rate (per 100,000 population)
2006
2001
1996
1991
1986
1981
1976
1971
1966
1961
1956
1951
1946
1941
100
200
300
400
500
Year

3. Gonorrhea—Rates by Sex, United States, 1990–2010
Total
Women
Men
Rate (per 100,000 population)
100
200
300
400
Year
2010
2008
2006
2004
2002
2000
1998
1996
1994
1992
1990

4. Gonorrhea—Rates by Region, United States, 2001–2010
South
Northeast
Midwest
West
Rate (per 100,000 population) 50
100
150
200
250
300
Year
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

5. Gonorrhea—Rates by State, United States and Outlying Areas, 2010
NOTE: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 99.6 per 100,000 population.

6. Gonorrhea—Rates by County, United States, 2010
Rate per 100,000
population
<19.0
(n = 1,408)
19.1–100.0
(n = 1,107)
>100.0
(n = 627)

7. Gonorrhea—Rates by Age and Sex, United States, 2010
15–19
20–24
25–29
30–34
35–39
40–44
45–54
55–64
65+
Total
Men
Women
Rate (per 100,000 population)
Age
750
600
450
300
150
253.4
421.0
241.3
146.5
85.1
64.2
34.1
94.1
2.4
11.0
570.9
560.7
226.3
107.5
48.2
23.8
9.0
106.5
0.5
1.9

8. Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2001–2010
Rate (per 100,000 population)
Year
200
400
600
800
1,000
35–39
40–44
30–34
25–29
20–24
15–19
Age Group
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

9. Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2001–2010
150
300
450
600
750
Rate (per 100,000 population)
Year
35–39
40–44
30–34
25–29
20–24
15–19
Age Group
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

10. Gonorrhea—Rates by Race/Ethnicity, United States, 2001–2010
Whites
Hispanics
Blacks
Asians/Pacific Islanders
American Indians/Alaska Natives
Rate (per 100,000 population)
Year
100
200
300
400
500
600
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

11. Gonorrhea—Cases by Reporting Source and Sex, United States, 2001–201040 80
120
160
200
STD Clinic, Women
STD Clinic, Men
Non-STD Clinic, Women
Non-STD Clinic, Men
Cases (in thousands)
Year
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

12. Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources, United States, 2010
Men
Women 5 10 15 20 25 30 35
STD Clinic
Private Physician/HMO*
Other HD* Clinic
Family Planning Clinic
Emergency Room
* HMO = health maintenance organization; HD = health department.
NOTE: These categories represent 69.5% of cases with known reporting source. Of all cases, 13.2% had a missing or unknown reporting source.

13. STD Surveillance Network­­ (SSuN)—Proportion of MSM,. MSW,
STD Surveillance Network­­ (SSuN)—Proportion of MSM,* MSW,* and Women Among Interviewed† Gonorrhea Cases by Site, 2010
Percentage
MSW
MSM
Women 20 40 60 80
100
Connecticut
New
York City
Philadelphia
Baltimore
Virginia
Alabama
Louisiana
Chicago
Colorado
Washington
California‡
San
Francisco
* MSM = men who have sex with men; MSW = men who have sex with women only.
† SSuN interviews conducted from a randomly selected patient population with gonorrhea (n = 3,446).
‡ California data excludes San Francisco.

14. Gonorrhea—Positivity Among Women Aged 15–24 Years Tested in Family Planning Clinics, by State, Infertility Prevention Project, United States and Outlying Areas, 2010
* States/areas not meeting minimum inclusion criteria.
NOTE: Includes states and outlying areas that reported positivity data on at least 500 women aged 15–24 years who were screened during 2010.

15. Gonococcal Isolate Surveillance Project (GISP)—Location of Participating Sentinel Sites and Regional Laboratories, United States, 2010

16. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Ceftriaxone Among GISP Isolates, 2006–2010 20 40 60 80
100
0.25
0.125
0.06
0.03
0.015
<0.008
2007
2006
Percentage
2008
2010
2009
MICs (µg/ml)

17. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Cefixime Among GISP Isolates, 2006 and 2009–2010 20 40 60 80
100
0.5
0.25
0.125
0.06
0.03
<0.015
Percentage
MICs (µg/ml)
2009
2006
2010
NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008.

18. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Azithromycin Among GISP Isolates, 2006–2010 10 20 30 40 16 8 4 2 1
0.5
0.25
0.125
0.06
<0.03
2007
2006
Percentage
2008
2010
2009
MICs (µg/ml)

19. Gonococcal Isolate Surveillance Project (GISP)—Percentage of Neisseria gonorrhoeae Isolates with Resistance or Intermediate Resistance to Ciprofloxacin, 1990–2010 5 10 15 20
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
Intermediate Resistance
Resistance
Percentage
Year
2010
NOTE: Resistant isolates have ciprofloxacin minimum inhibitory concentrations (MICs) >1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125–0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990.

20. Gonococcal Isolate Surveillance Project (GISP)—Penicillin, Tetracycline, and Ciprofloxacin Resistance Among GISP Isolates, 2010
PenR/QRNG
PenR
TetR/QRNG
PenR/TetR
QRNG
PenR/TetR/QRNG
TetR
Susceptible
72.8%
1.8%
6.9%
2.0%
2.9%
9.4%
3.5%
0.6%
NOTE: PenR = penicillinase producing Neisseria gonorrhoeae and chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae.

21. Gonococcal Isolate Surveillance Project (GISP)—Drugs Used to Treat Gonorrhea Among GISP Participants, 1988–2010
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010 20 40 60 80
100
Ceftriaxone 125 mg
Spectinomycin
Ceftriaxone 250 mg
Cefixime
Penicillins
Ciprofloxacin
Tetracyclines
Ofloxacin
Other
Percentage
Year
Other Cephalosporins
NOTE: For 2010, “Other” includes no therapy (1.2%), azithromycin 2 g (1.7%), and other less frequently used drugs.